Axial Spondyloarthritis Pipeline Review, H1 2018 - Analysis by Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Axial Spondyloarthritis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders).

Companies Mentioned

  • AstraZeneca Plc
  • Eli Lilly and Co
  • Fresenius SE & Co KGaA
  • Novartis AG
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Axial Spondyloarthritis - Overview
  4. Axial Spondyloarthritis - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Axial Spondyloarthritis - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Axial Spondyloarthritis - Companies Involved in Therapeutics Development
  14. AstraZeneca Plc
  15. Eli Lilly and Co
  16. Fresenius SE & Co KGaA
  17. Novartis AG
  18. Sandoz International GmbH
  19. Sun Pharma Advanced Research Company Ltd
  20. UCB SA
  21. Axial Spondyloarthritis - Drug Profiles
  22. Axial Spondyloarthritis - Dormant Projects
  23. Axial Spondyloarthritis - Product Development Milestones
  24. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/jd7ldm/axial?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs